A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658 ↗

Phase 2 Completed 275 enrolled CinCor Pharma, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

Timeline

Start: 2020-10-12
Primary completion: 2022-06-14
Completion: 2022-06-14

Publications

Background Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Baxdrostat	Small molecule	0.5 mg	Oral
Subject	Baxdrostat	Small molecule	1 mg	Oral
Subject	Baxdrostat	Small molecule	2 mg	Oral

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

Summary

Timeline

Publications

Drugs

Indications